Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etafedrine SCHEMBL14643068 | 1.00 | KDM4E (0.68) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| Etafedrine SCHEMBL14384530 | 1.00 | KDM4E (0.68) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| Etafedrine SCHEMBL123128 | 0.98 | ALDH1A1 (0.66) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| Etafedrine SCHEMBL1649039 | 0.96 | KDM4E (0.63) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| SCHEMBL13359192 | 0.87 | KDM4E (0.61) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| SCHEMBL14024243 | 0.85 | KDM4E (0.63) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| SCHEMBL11127338 | 0.85 | KDM4E (0.63) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| SCHEMBL2712000 | 0.84 | KDM4E (0.62) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| SCHEMBL30062527 | 0.83 | ALDH1A1 (0.61) | KDM4EALDH1A1AOC3GAASLC6A4 | |
| SCHEMBL22547531 | 0.82 | AOC3 (0.61) | KDM4EALDH1A1AOC3GAASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 878 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | claimed |
| US-20190046471-A1 | Methods and Compositions for the Treatment of Steatosis-Associated Disorders | DUKE UNIVERSITY | 2019-02-14 | — | — | US | claimed |
| EP-3344337-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CYTOPPLASMIC GLYCOGEN STORAGE DISORDERS | Duke University (US) | 2018-07-11 | — | — | EP | claimed |
| WO-2017049157-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STEATOSIS-ASSOCIATED DISORDERS | DUKE UNIVERSITY (US) | 2017-03-23 | — | — | WO | claimed |
| WO-2017049161-A1 | ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER | DUKE UNIVERSITY (US) | 2017-03-23 | — | — | WO | claimed |
| WO-2017040647-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CYTOPPLASMIC GLYCOGEN STORAGE DISORDERS | DUKE UNIVERSITY (US) | 2017-03-09 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20050130935-A1 | Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders | ASTION DEVELOPMENT A/S (DK) | 2005-06-16 | — | — | US | claimed |
| EP-1496917-A1 | COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS | Astion Development APS (DK) | 2005-01-19 | — | — | EP | claimed |
| EP-1476142-A1 | COMPOSITIONS FOR PULMONARY ADMINISTRATION | ORION CORPORATION (FI) | 2004-11-17 | — | — | EP | claimed |
| WO-2003097073-A1 | COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS | ASTION DEVELOPMENT A/S (DK) | 2003-11-27 | — | — | WO | claimed |
| WO-2003061637-A1 | COMPOSITIONS FOR PULMONARY ADMINISTRATION | ORION CORPORATION (FI) | 2003-07-31 | — | — | WO | claimed |
| CN-1358178-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-07-10 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4160099-A | Labile, non-heterocyclic quaternary ammonium salt/esters as transient derivatives | INTERX RESEARCH CORPORATION | 1979-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | KDM4E 2292/4885ALDH1A1 1389/4885AOC3 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.